+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Companion Diagnostics Market by Technology, Indication, End-user - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5336915
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Companion Diagnostics Market grew from USD 6.64 billion in 2023 to USD 7.30 billion in 2024. It is expected to continue growing at a CAGR of 10.65%, reaching USD 13.49 billion by 2030.

Companion diagnostics, integral to personalized medicine, are tests or tools used alongside therapeutic products to guide treatment decisions in oncology, cardiovascular, infectious diseases, and more. Their necessity stems from the need to tailor treatments based on genomic, proteomic, and metabolic information specific to individuals or subgroups. These diagnostics support more effective treatment regimens, minimize adverse effects, and improve clinical outcomes, thus gaining increasing importance, particularly in cancer therapy where they aid in identifying patients most likely to benefit from a particular treatment. Their application spans from biomarker discovery and validation processes to clinical trial stratification and routine clinical use, primarily within hospitals, diagnostic labs, and healthcare institutions. The market, driven by technological advances in genomic sequencing and the push towards precision medicine, s continually expanding. However, factors like high costs of diagnostic tests, regulatory challenges, and complex reimbursement scenarios pose significant hindrances to market growth. Another challenge includes the heterogeneity in disease presentations, necessitating highly specific diagnostic tools that often require extensive validation.

To capitalize on emerging opportunities, companies should explore collaborative partnerships with biopharmaceutical firms, leveraging advancements in digital health technologies for real-time disease monitoring and diagnostic accuracy improvement. Investing in R&D for multiplexed diagnostic platforms and integrating machine learning for predictive analytics can present substantial growth prospects. Furthermore, addressing regulatory barriers by engaging with health authorities early in the development process can drive faster commercialization. Innovations in liquid biopsy and next-generation sequencing (NGS) offer novel avenues for research, especially in oncological applications where early detection is crucial. As the market is marked by rapid technological evolution, maintaining agile operations and a strong focus on adaptive R&D will be vital for sustained business growth and leadership in the field of companion diagnostics.

Understanding Market Dynamics in the Companion Diagnostics Market

The Companion Diagnostics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing significance of companion diagnostics in drug development
    • Increasing demand for personalized medicines and targeted therapy
    • Rise in research and development for innovation in next generation sequencing
  • Market Restraints
    • High costs associated with development and implementation of companion diagnostics
  • Market Opportunities
    • Ongoing technological advancements in diagnostic techniques
    • Favorable regulatory policies encouraging the development and approval of companion diagnostics
  • Market Challenges
    • Reimbursement issues associated with companion diagnostic tests

Exploring Porter’s Five Forces for the Companion Diagnostics Market

Porter’s Five Forces framework further strengthens the insights of the Companion Diagnostics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Companion Diagnostics Market

External macro-environmental factors deeply influence the performance of the Companion Diagnostics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Companion Diagnostics Market

The Companion Diagnostics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Companion Diagnostics Market

The Companion Diagnostics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Companion Diagnostics Market

The Companion Diagnostics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMérieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Companion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Technology
    • Immunohistochemistry
    • In Situ Hybridization
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Indication
    • Cancer
      • Blood Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurological Disorders
  • End-user
    • Pharmaceutical & Biopharmaceutical Companies
    • Reference Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing significance of companion diagnostics in drug development
5.1.1.2. Increasing demand for personalized medicines and targeted therapy
5.1.1.3. Rise in research and development for innovation in next generation sequencing
5.1.2. Restraints
5.1.2.1. High costs associated with development and implementation of companion diagnostics
5.1.3. Opportunities
5.1.3.1. Ongoing technological advancements in diagnostic techniques
5.1.3.2. Favorable regulatory policies encouraging the development and approval of companion diagnostics
5.1.4. Challenges
5.1.4.1. Reimbursement issues associated with companion diagnostic tests
5.2. Market Segmentation Analysis
5.2.1. Technology: Increasing preference of next-generation sequencing in precision medicine
5.2.2. End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Companion Diagnostics Market, by Technology
6.1. Introduction
6.2. Immunohistochemistry
6.3. In Situ Hybridization
6.4. Next-Generation Sequencing
6.5. Polymerase Chain Reaction
7. Companion Diagnostics Market, by Indication
7.1. Introduction
7.2. Cancer
7.2.1. Blood Cancer
7.2.2. Breast Cancer
7.2.3. Colorectal Cancer
7.2.4. Lung Cancer
7.3. Cardiovascular Diseases
7.4. Infectious Diseases
7.5. Neurological Disorders
8. Companion Diagnostics Market, by End-user
8.1. Introduction
8.2. Pharmaceutical & Biopharmaceutical Companies
8.3. Reference Laboratories
9. Americas Companion Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Companion Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Companion Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care
12.3.2. Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development
12.3.3. Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne® CDx Diagnostic Advances
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 41. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 45. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 63. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 67. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 75. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 99. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 112. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 116. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 120. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 124. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 128. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 136. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 148. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 152. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 156. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 170. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 172. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 184. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Companion Diagnostics Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Abnova Corporation
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • Almac Group
  • Amoy Diagnostics Co., Ltd.
  • ARUP Laboratories
  • Bio-Techne Corporation
  • Biogenex Laboratories, Inc
  • bioMérieux SA
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Guardant Health, Inc
  • ICON PLC
  • Illumina, Inc.
  • Invivoscribe Technologies, Inc.
  • Myriad Genetics, Inc.
  • NG biotech
  • QIAGEN N.V.
  • R-Biopharm AG
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information